Agios Pharmaceuticals (AGIO): next trial readout expected around 2028-01-17
$AGIO · Agios Pharmaceuticals, Inc.Trials that could report in the next 12 months: 1BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything AGIO is running — see methodology.
- 2028-01-17in 74wA Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharma… | Phase 1 | Recruitingstill enrolling patients | 2028-01-17 | NCT07241234 |
| A Study to Provide Access to Mitapivat for Participants Who Previously… | Phase 4 | Enrolling By Invitation | NCT05777993 | |
| A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of M… | Phase 3 | Recruitingstill enrolling patients | NCT07506863 | |
| A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of M… | Phase 3 | Recruitingstill enrolling patients | NCT07517133 | |
| A Study to Investigate the Effect of Mitapivat on Transfusion Burden i… | Phase 3 | Recruitingstill enrolling patients | NCT07656415 |
Status-change history
Every ClinicalTrials.gov change recorded for AGIO's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is AGIO's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is AGIO's lead program in?
Phase 3 — recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.